Akorn Reviews Future Of Consumer Health Portfolio
Company Considers Divesting Brands For Financial Flexibility
US injectables specialist Akorn has begun to review strategic alternatives for its consumer health business, as the company looks at divesting some of its brands to increase financial flexibility and focus on its prescription generic and branded portfolio.
